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Whereas parturients with procoagulant defects usually present with delayed onset of bleeding, those with platelet or 'vascular' abnormalities often give a history of epistaxis, mucocutaneous bleeding, menorrhagia, easy bruising and persistent, immediate bleeding after trauma. This paper will deal with the more important acquired and congenital haematological coagulation, platelet and vascular disorders responsible for last trimester bleeding in the obstetric patient. Unfortunately, torrential and catastrophic bleeding during delivery is still often mismanaged because the problem is approached in somewhat different manner by the two disciplines: (a) the clinical anaesthetist, who may have little real understanding of the ever-expanding array of special investigations, and (b) the laboratory, which is usually unsympathetic to the point in the dynamic clinical process at which the investigations were carried out. 
Maternal considerations
Described by Professor Eric von Willebrand of Helsinki in 1926, this inherited disorder (vWd) is a spectrum of lesions of the pleiotropic gene for a factor VIII component (VIIIvWF or VIIIR:WF or VIII:CoF).1,2 vWd is usually transmitted in autosomal dominant pattern with mixed penetrance and variable expressivity. Less common, and often more severe, variants are inherited as either X-linked or autosomal recessive patterns. The disorder can present as either a quantitative (type I) deficiency or as a qualitative (type 11) factor VIII defect. 3 The multimeric, high molecular weight VIII complex is synthesised in endothelial cells and megakaryocytes. 3 It is present in procoagulant and active forms. The factor VIII complex occurs in platelets, plasma and endothelial cells and has three components: 1. VIII vWF (or VIII related ristocetin CoFactor, VIIIR:CoF) which is a plasma protein essential for platelet aggregation, adhesion to subendothelial collagen and formation of the primary haemostatic plug. If the level of VIII vWF is low, the bleeding time (BT) is prolonged. 13 VIII vWF is also necessary for ristocetin induced platelet aggregation but does not participate in the coagulation cascade. 35 2. VIII:Coag (or VIII:C), which, in its active form (VIlla), activates factor X in the presence ofIXa and Calcium, i.e. it is a Factor IXa accelerator (see Fig. 2 ).13 3. VIIIR:Ag, which precipitates with rabbit antibody.4 A diagnosis of vWd is suggested to the anaesthetist by a personal and family history of platelet-type bleeding problems (e.g. menorrhagia, mucosal bleeding) and confirmed by further testing and review by a haematologist. Patients with vWd The plasma VIII levels as judged immunologically are diminished (though they are not as profoundly depressed as in haemophilia A). There are variants, however, which exhibit normal immunological levels but have deficient functional activity. 2, 3, 7 In normal pregnancy, many changes occur in the levels of procoagulants in the coagulation sequence. As can be seen in Table 2 , factors I, VII, VIII, IX and X are elevated in late pregnancy with factors 11 and V being affected to a much smaller extent. 35, 48 In patients with vWd there is usually spontaneous, gradual correction of the haemostatic defect as the pregnancy progresses. 7 ,1O This improvement is not due to cross-placental transfer of fetal factor VIII because VIII level rises even if the fetus is later proven to have vWd. In all pregnancies, there is a state of chronic intravascular coagulation localised to the placental bed. Placental platelet trapping together with haemodilution account for the platelet count of 150-350 x 10 9 /1 in late pregnancy.4 Factor VIII may be increased by up to four times the pre-pregnancy levels in normal individuals the rise in Factor VIII beginning around the second to third month of pregnancy.8, 35 Factor VIII-related antigen (VIIIR:Ag), VIIICoag (VIIIC), platelet adhesiveness and VIIIvWF all usually increase in pregnancy.1O Sometimes increases in VIII:Coag and VIIIR:Ag are not associated with correction of the prolonged BT.9 The bleeding time is the anaesthetist's best parameter of suitability for regional techniques and the need for replacement therapy. Bleeding time should be performed often and used as a guide to deciding if a major conduction block is safe. Even though there may be little or no bleeding during delivery, post partum haemorrhage is not uncommon because the haemostatic defect reappears rapidly after delivery.5
Anaesthetic considerations
If, at term, VIII related antigen (VIIIR:Ag) and VIII ristocetin Cofactor (VIIIvWF) are above 50% and ifBT is borderline or normal, it is reasonable to allow the patient to deliver vaginally. It may be unwise to initiate major conduction blocks (e.g. extradural) in these patients because, though only minor epidural bleeding may occur intra partum, as the VIII level plummets post partum, rebleeding may occur. Because the pudendal nerve lies so close to the artery and vein, puncture of these vessels with secondary haematoma formation is possible. Pudendal block is therefore relatively contraindicated unless the bleeding time is normal. Narcotics and inhalational analgesia (nitrous oxide, trichlorethylene, methoxyflurane) are more reasonable alternatives. Perineal infiltration and judicious use of narcotics or ketamine can be used to supplement analgesia for minor procedures (e.g. repair of episiotomy). Patients with prolonged BT and VIIIR:Ag and VIIIvWF (VIIIR:CoF) of less than 50% should initially be treated with the vasopressin analogue desmopressin (DDA VP). 35 Cryoprecipitate, which is stable for six months at -30· C, may be necessary if bleeding persists. It is the component replacement of choice because (1) Factor VIII concentrate is ineffective in treating vWd because the purification process damages or inactivates VIII vWF, (2) the serum hepatitis B risk is even lower than risk from administering whole blood (and may be reduced by using glycine precipitate), (3) volume delivered is low (undiluted cryoprecipitate 13 ml, diluted cryoprecipitate 30-50 ml vs fresh frozen plasma 200 ml), (4) cryoprecipitate corrects the prolonged BT, and (5) the rise in VIII level achieved in the patient is greater than can be explained by VIII content in the infusion of cryoprecipitate ('overresponse' is due to induced VIII synthesis). 1,1 1,16,35 Unfortunately, cryoprecipitate cannot be heat-treated. 13 AHF KABI® contains VIII:Coag, fibrinogen, XIII and VIII VWF. 13 Interestingly, following cryoprecipitate or plasma administration, there is an immediate rise in VIII level followed by a gradual secondary rise which continues for 48 hours. IS Since the plasma t112 of VIII is about twelve hours, a common dose of cryoprecipitate is one unit (bag) for every 6 kg body weight just prior to delivery. 11, 12 The VIII level should be maintained above 25% for some days post partum. 7.0 mm ID), lubricated endotracheal tube placed. Blood loss should be treated aggressively using whole blood, packed red blood cells, cryoprecipitate and plasma.
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IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP) Maternal considerations
In ITP, an IgG 3 antiplatelet auto-antibody binds to platelet membrane glycoproteins Ib, lib and IIla. 35 ,45 Though it does not fix complement, the IgG 3 antibody-coated platelets are recognised and prematurely destroyed by reticulo-endothelial cells (especially splenic macrophages). 45 Platelet survival time may be reduced from ten days to 50-230 minutes. 5 ITP is predominantly a disease of young women, and in pregnancy, possibly due to an oestrogen effect, there is usually a worsening of the thrombocytopenia. 35 ,46 Mothers in remission will often relapse. 2 ,46 Transfused donor platelets suffer the same fate as native circulating platelets. Platelet replacement transfusion may actually be counterproductive. Transfused platelets are rapidly scavenged and antiplatelet antibody production can be accelerated.
The diagnosis is suggested to the anaesthetist by a past history of purpura, ecchymosis and bleeding and confirmed by the presence of thrombocytopenia, prolonged bleeding time,
There is wide variation in factor VIII activity in individual bags of cryoprecipitate but cryoprecipitate is considered acceptable for transfusion if the average procoagulant VIII activity is more than 80 IU perbag. 16 It ranges from 60 to 126 unitslbag. 19 Whereas fresh frozen plasma (FFP) contains 0.7-1.0 units of VIII clotting factor activity (per 1 ml plasma), cryoprecipitate contains Factor VIII replacement continues for several days <{ post partum. However, it may be wise to abandon ~ major local conduction anaesthetic block if bleeding occurs at needle or catheter placement or
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• if the procedure proves technically difficult even if the laboratory and in vivo tests are normal. Regional techniques should not be attempted in an incompletely prepared patient presenting for emergency surgery. In these patients, at least two sites of intravenous access larger than 16 gauge should be secured. After induction, gentle laryngoscopy should be performed and a small (6.5- Since intracranial haemorrhage in the neonatal infant of an ITP mother is a major cause of morbidity or death, delivery is usually by cesarean section or atraumatic vaginal delivery.
Fetal considerations
In ITP, perinatal mortality in modem neonatal practice is low but about ten percent of all live-born infants have a significant haemostatic defect. 46 IgG antibodies cross the placenta producing fetal thrombocytopenia. As can be seen in Figure 3 , there is no correlation between fetal and maternal platelet counts in ITP.38 There is, however, an approximate correlation between level of maternal anti platelet antibody and risk of infant thrombocytopenia. 15, 48-50 Unfortunately, monitoring the maternal circulating platelet antibody or platelet-associated antibody is not completely effective in determining fetal bleeding risk. 35, 38 The administration of steroids to the mother to increase maternal platelet count does not guarantee a platelet count in the neonate adequate for haemostasis. 2 Fetal capillary blood sampling seems to be the only way to determine fetal platelet count. 38 If fetal scalp platelet count is less than 50 x 10 9 11, immediate caesarean delivery should be performed; if more than 50 x 10 9 11, vaginal delivery is allowed to proceed.
Placental transfer of prednisone is higher than that of betamethasone and dexamethasone. Prednisone is the steroid of choice for treating ITP in pregnancy. '
Anaesthetic considerations
The aims of management are to prevent, identify and treat (1) maternal and fetal thrombocytopenia and haemorrhage, and (2) fetal intracranial haemorrhage of prematurity, thereby reducing overall morbidity and mortality.
Platelet transfusions are reserved for patients who have either significant haemorrhage and low platelet count (say, 20 x 10 9 11) or who will be undergoing surgery and are thrombocytopenic.
One unit of platelet concentrate should raise the platelet count by 5-10 x 10 9 /1. 6 ,7 Platelets should be administered via a 'short' intravenous administration set without a filter. Since platelet survival time may be of the order of minutes, platelet transfusions should be 'covered' with a dose of prednisone. Aim to bring the platelet count to more than 60 x 10 9 /1, and to normalise the BT (Figure 4 ). It is not necessary to bring the platelet count to 'normal'. 35 A course of 1.0 to 1.5 mglkglday prednisone will usually increase the platelet count in 7-10 days and decrease purpura in a few days.3s Most of these patients will be on steroids for a significant proportion of their pregnancy and will require additional doses prior to, during and after anaesthesia and delivery. These patients require careful preoperative assessment both with regard to their bleeding potential and with reference to their medications for ITP which may include immunosuppressives and antimetabolites (e.g. vinca alkaloids), colchicine, danazol (a weak androgen), and high dose gamma-globulin. Should thrombocytopenia fail to respond to other modalities, 0.4 gm/kg of intravenous IgG may be. given intravenously slowly prior to surgery.14,SO Immunoglobulin may (but does not always) correct the thrombocytopenia. Some ofthese patients may present to the anaesthetist for splenectomy in the second trimester to control or cure their ITP. 35 Patients with prolonged BT, platelet count < 100 X 10 9 /1 and abnormal clot retraction should not receive major conduction anaesthesia or intramuscular injections (e.g. anticholinergic premedication, if used, should be administered IV). Suitable alternatives for analgesia in labour include parenteral narcotics or inhalational agents, e.g. methoxyflurane, 'Entonox' (nitrous oxideoxygen mixture) with adjunctive perineal infiltration, IV narcotics or low-dose ketamine for minor operative procedures. Drugs which adversely affect platelet function should be avoided.
Since antibody is cleared from the neonate with a t1f2 of 23 days, the infant's tl\rombocytopenia (caused by maternal transplacental antibodies) is usually rectified within 2-12 weeks. 35 Nevertheless, the infant's platelet count continues to fall after delivery, reaching its nadir within one week of delivery. 46 In the meantime, the baby may require support with platelet or exchange transfusions.
DRUG INDUCED THROMBOPATHY
AND THROMBOCYTOPENIA Drug induced platelet dysfunction or diminished number is relatively common in the general population, but much less so in pregnancy because medical practitioners are reluctant to administer medications to pregnant patients. 35 Since there is usually no change in platelet count as a result of the pregnancy per se, a low platelet count should be investigated and drug platelet abnormalities excluded. 39 Whenever it is suspected, a platelet count and bleeding time should be obtained prior to initiating regional blockade.
Thrombocytopenia can be due to an immune complex 'innocent bystander' effect, direct generalised bone marrow depression (e.g. chloramphenicol), or a selective effect on the platelet series in bone marrow (e.g. thiazides). 42, 43 Thrombopathia can be due to abnormal aggregation (e.g. aspirin) or interference with ADP or serotonin release. 5 Many methods are available for detecting antiplatelet antibodies including platelet aggregometry, release of serotonin or 51 Cr from damaged platelets, complement fixation or antiglobulin consumption.
Anaesthetic considerations
Though N 2 0 and volatile anaesthetics decrease ADP-induced platelet aggregation in vitro short exposures are not contraindicated. 22 The local anaesthetics, benzdiazepines, a-adrenergic antagonists, 6-blockers, nitroprusside, nitroglycerin, hydralazine and antihistamines can induce platelet dysfunction while the barbiturates, antihistamines, methyldopa, heparin and phenothiazines can produce thrombocytopenia. 5 Nevertheless, single doses of these drugs are unlikely to produce any untoward effects. In practical terms, this means that prolonged usage of these drugs should be carefully monitored.
If a drug-induced thrombopathy or thrombocytopenia occurs, the medication should be stopped immediately and, if the problem is severe, steroids, intravenous IgG or platelet transfusion may be necessary.
Regional techniques are contraindicated if (a) bleeding time is prolonged and platelet count is > 50 X 1 0 9 11, (b) platelet count is < 50 X 10 9 /1, or (c) the patient has petechiae or ecchymoses. In subgroups (b) and (c), above, a bleeding time is unnecessary as it will be prolonged. 41 ,42 Bleeding time is usually normal if platelet count is > 100 X 10 9 /1 (see Figure 4 ). 28 The PT and PTT are normal in drug induced thrombopathy. HAEMOPHILIA A (CLASSICAL HAEMOPHILIA)
Material considerations
The familial small component antihaemophilic factor, VIII:Coag (also known as AHF:C or VIII:C) anomaly which occurs in classical haemophilia is an X-linked inherited disorder. It produces only a carrier state in females. Full-blown haemophilia is rare in pregnant females. Significant VIII:Coag activity depression in the mother will only occur if she is homozygous, develops lyonisation or has a spontaneous gene mutation. 2 ,5 Haemophilia A patients have a low VIII:Coag but normal VIII vWF and VIIIR:Ag. Some protection is afforded by the pregnancy because factor VIII level and activity normally increase in both normal and haemophilic pregnancies ( Table 2) .
The diagnosis is suggested by the past history and confirmed by a prolonged aPTT and whole blood clotting time and reduced VIII:Coag activity. In haemophilia, aPTT is a particularly useful screening test because it is prolonged in all but the mildest cases. Besides, the BT, PT and TT are often normal.
An uncommon but intriguing cause of post partum bleeding is the development of anti-VIII antibodies in the puerperium. 2
Fetal considerations
Though maternal VIII:Coag does not cross the placenta, spontaneous bleeding in the fetus or in the infant during delivery is uncommon. 2
Anaesthetic considerations
The preoperative assessment should take into account the possibility that these patients may be receiving immunosuppressants, steroids, or Autoplex® (activated clotting factors) and may have had recent exchange transfusion or plasmapheresis. The normal non-pregnant patient has one unit VIII:Coag activity per ml of plasma (i.e. 2500 VIII:Coag activity total) which represents 100% activity (normal range 50-100% 
Maternal considerations
Since IX:Coag deficiency is transmitted as X-linked recessive producing only a carrier state in females, this condition is rare in parturients. It can occur in the homozygous state or in a carrier retaining abnormal coagulation. 2 ,5 It is diagnosed from the past and family history and from a low or absent Factor IX concentration on specific assay and a prolonged PTT in the presence of normal VIII activity (see Figure 1 ).22
Fetal considerations
Bleeding in the infant at labour and delivery is uncommon. 2
Anaesthetic considerations
Procoagulant IX has a larger volume of distribution but a longer biological t1f2 of 24 hours than Factor VIII. 5 Factor XI deficiency, while quite rare, is (probably) transmitted as an autosomal recessive and is, consequently, occasionally encountered in pregnancy. It is usually, but not always, a mild defect. It is treated with fresh frozen plasma or whole blood.
Factor VII deficiency may be severe and affects females. A specific Factor VII component therapy is now available.
Congenital Fibrinogen (I), Factor V, Factor XIII and Prothrombin (11) deficiencies are all very rare conditions.
HEPATIC DISEASE
A number of functional, physiological and histological changes occur during pregnancy (Table  4 ). In pregnancy, hepatic blood flow remains the same in the prepregnant state even though the plasma and blood volumes increase and cardiac output is 50% more than the prepregnant values. This results in the percentage of blood delivered through the liver being decreased by 35%. 32 Pregnancy is associated with a number of diseases of the liver (e.g. cholestasis of pregnancy, acute fatty liver of pregnancy, hepatic rupture and haematoma in eclampsia and tetracycline-induced fatty liver of pregnancy). A number of disorders of pregnancy also affect the liver (e.g. pre-eclampsia and eclampsia, pyelonephritis, hyperemesis gravidarum and cholelithiasis). 35 Taking into consideration all the other hepatic diseases which parturients are exposed to (including viral A, B & non-A non-B hepatitis, alcoholic liver disease, hepatic cirrhosis and drug hypersensitivities) it comes as little surprise that women in late pregnancy with liver impairment are not infrequently encountered. 32 Liver disease accentuates the coagulation 'disorder' of pregnancy (e.g. elevated monoclonal d-Dimer). Significant coagulopathy does not occur, however, until severe liver disease is present. 
Anaesthetic considerations
Apart from the bleeding disorder, there are several other important considerations when planning anaesthesia for patients with fulminant liver disease. These patients may be encephalopathic and profoundly hypoglycaemic (from hyperinsulinism and failure of hepatic gluconeogenesis). They may have secondary renal failure (from endotoxaemia), respiratory failure (from intrapulmonary shunting, pulmonary oedema, ARDS and diaphragmatic mechanical impairment by ascites), acid-base disorders (usually mixed respiratory and non-respiratory alkalaemia), acute haemorrhagic pancreatitis (10%) and electrolyte imbalance (usually hypo-kalaemia, -natraemia, -phosphataemia). They are intolerant of changes in plasma volume and commonly have cardiac dysrrhythmias (from myocardial petechial haemorrhages and pericarditis). It is beyond the Anaesthesia and Intensive Care, Vol. 18. No. 3. August. 1990 scope of this article to discuss the anaesthetic management of parturients with these complex disorders. It should suffice to briefly consider each group of anaesthetic agents to enable us to make an appropriate choice of agents and techniques.
Induction agents. Thiopentone (Pentothal®, Intraval®), methohexitone (Brevital®, Brietal®) and hexobarbitone are metabolised in the liver but recovery is achieved primarily by redistribution. Propanidid (Epontol®) is metabolised by liver cholinesterase and alphaxolone + alphadolone (Althesin®) is rapidly taken up in liver and excreted in bile 33 • Ketamine should be avoided when the liver disease is secondary to pregnancy-induced hypertension or in chronic alcoholics.
Neuromuscular blockers. Most neuromuscular blockers have predominantly renal excretion. Nevertheless, pancuronium and d-tubocurarine are handled in the liver to a much greater extent than succinylcholine (suxamethonium), atracurium, fazidiniun or gallamine. In patients with fulminant liver disease requiring a non-depolariser, atracurium is becoming the drug of choice.
Inhalational agents. In vitro studies show that N 2 0 can produce thrombocytopenia. Cyclopropane increases splanchnic vascular resistance. Following halothane exposure, there is a 1/35,000 incidence of halothane hepatitis. Chloroform centrilobular necrosis is reported in 1/13,000 exposures. There are isolated reports of methoxyflurane-associated, immunologically mediated hepatitis and enflurane-induced liver damage. Ether can produce mild elevations ofliver enzymes and fluroxene's metabolite trifluoroethanol can cause hepatic damage. Chloroform, ether, cyclopropane, fluroxene and methoxyflurane are mentioned here mostly for historical reasons and also because some of these agents are still used for anaesthesia or analgesia in labour in some areas. 12 Unlike halothane, isoflurane and enflurane do not produce hepatotoxicity in animals with induced enzymes who are made hypoxic. In practice, isoflurane seems to be the agent of choice.
Local anaesthetics. Are all potentially harmful to patients with liver disease because the amides are metabolised by liver microsomes and the esters by liver and plasma cholinesterases. Major regional techniques (as well as general anaesthesia) can decrease liver blood flow. Because most of these patients have severe coagulopathy, major conduction block techniques (e.g. epidural analgesia) will be contraindicated on other grounds.
Opioids, benzodiazepines and phenothiazines. Parturients in liver failure have increased sensitivity to these agents. A single, relatively small dose of almost any lipid-soluble drug can tip them into hepatic coma.
Catecholamines, vasopressors and parasympatholytics (e.g. atropine, scopolamine). All are partially metabolised in the liver.
Anaesthesia in any patient with fulminant liver disease is a hazardous undertaking. General anaesthesia using judicious doses of barbiturate as induction agent, atracurium as muscle relaxant and isoflurane or enflurane as inhalational agent may well be the technique of choice.
ANTICOAGULATION AND VITAMIN K DEFICIENCY
Heparin
Heparin inhibits serine proteases in the clotting cascade especially X = > Xa (but also I1a, IXa, Xla, kallikrein & XIII). 21, 22, 44 It does this by accelerating the action of the a~-globulin, plasma heparin co-factor, antithrombm III (AT Ill). Minidose heparin mainly inhibits IXa. Since the coagulation cascade is essentially an amplification system, the inhibition of 1 unit of Xa by AT III prevents the production of 50 units of thrombin. 21 Once thrombin is formed, far more heparin is needed to allow neutralisation of I1a by AT 111.21 100 IV of heparin are antagonised by 1 mg of protamine. 22 Heparin, which has a dose-dependent t1f2 of about 1.5 hours, is inactivated in liver by heparinase and excreted by the kidney.23 Heparin does not cross the placental barrier.
Coumarins and Indandiones
Oral anticoagulants interfere with Vitamin K-dependent procoagulant (11, VII, IX, X) synthesis. 22 . 36 It is antagonised in 3-6 hours by IM Vitamin K. In low dose, coumarin inhibits mainly VII; in high dose, effect is on all the Vitamin K-dependent factors.
Vitamin K
Vitamin K, whose gastrointestinal absorption is facilitated by bile salts, is utilised in the liver to synthesise procoagulants 11, VII, IX and X.22 Vitamin K may be deficient in obstructive jaundice, malabsorption syndromes and malnutrition. The PT is a more sensitive test of Vitamin K deficiency than aPIT because factor VII has a short til2. However, if deficiency of other factors (such as XI) develops both the PT and the aPTT will be prolonged.
Anaesthetic considerations
'Minidose' heparin. Heparin 5000 IV t.i.d. S.c. probably represents the maximum amount of heparin that can be administered daily without producing significant haemorrhagic complications during surgery. There is still considerable controversy as to whether regional techniques should be employed in patients on prophylactic low-dose heparin.
It is our practice to allow conduction anaesthesia (including extradural catheter insertion) to be employed provided (1) ACT and PIT are normal, (2) heparin is being used at a dose smaller than 5000 IV b.i.d., and (3) the technique is immediately abandoned should 'bloody tap' occur. Some authorities feel that 'single-shot' (but not catheter insertion) is reasonable in these patients. 24 Minidose heparin may be restarted three hours after the conduction block is discontinued. 5 Full heparinisation. All major regional techniques (including spinal, epidural, pudendal and paracervical block) are contraindicated in anticoagulated parturients because of the risk of uncontrollable bleeding. Heparin has a mean biological til2 of 100 min. 23 Half-life varies with the individual, dosage, body temperature and the presence ofhepato-renal disease. Surgery should be planned to occur four to five hours after the last dose of heparin in patients who need anticoagulation. 5 Extent of heparinisation is monitored using ACT (control normal: 120-150 sec), PTT or aPTT (PTTK), thrombin clotting time (TCT), whole blood clotting time (WBCT), heparin-protamine titration and heparin assay. 25, 27 Care must be exercised during protamine reversal (see above for dosages) in parturients because protamine occasionally produces adverse cardiovascular responses, can exhibit idiosyncratic and anaphylactic reactions and can produce the 'catastrophic' pulmonary vasoconstriction syndrome. 26 In heparinised patients, upper airway manoeuvres should be performed expertly and gently. Intramuscular medication should be avoided.
Coumarin and Vitamin K Deficiency. The same warnings as for fully heparinised patients apply to orally anticoagulated and Vitamin K deficient patients. These parturients are monitored using PT. 27 If PT is about 1.5x normal, FFP is usually not indicated. 36 Immediate treatment consists of FFP (which contains 11, VII, IX and X) or Prothrombinex® (freeze dried 11, IX, X) infusions because parenteral Vitamin K (which should be given at the same time) takes three to six hours to produce an effect. Prothrombinex 10 ml is equivalent to 200-300 ml FFP.II Prothrombinex is inappropriate if anticoagulation needs to be reversed quickly because it does not correct the induced Factor VII deficiency. Each unit of FFP will increase the level of any clotting factor by 2_3%. 36 Once an intramuscular dose of 10-25 mg Vitamin Kl is given, oral anticoagulation cannot be re-established for two weeks.27 COAGULOPATHY OF MASSIVE BLOOD TRANSFUSION Massive blood transfusion is often associated with a multifactorial clotting disorder. This coagulopathy may be due to: 1. Platelet dilutional 'washout':
Blood stored for more than 48 hours at 4°C has less than 2% viable platelets. 31 Transfusion of more than 15 units of platelet-poor banked blood will reduce platelet count to a critical level of less than 100 X 10 9 IVs 2. Procoagulant V and VIII dilution:
Banking of blood will cause factors V and VIII to fall. Most of the other procoagulants are stable in banked blood. 22 Transfusions of large amounts of stored blood rarely dilutes plasma concentration to less than 50%.31 Only 5-20% of factor V and 30% of factor VIII is necessary for haemostasis in surgery. The coagulopathy is due to release of thromboplastic substances (e.g. erythrocin) from erythrocyte stroma and Ag-Ab activation of Hageman factor, platelets and leucocytes producing disseminated intravascular coagulation (DIC). 4. Platelet-specific antibodies producing 'posttransfusion purpura': Platelets share HLA Ags with leucocytes so that sensitisation to platelet-specific Ags may cause platelet injury. 30 
Acute haemolytic transfusion reactions:
Depletion of ATP stores:
ATP depletion produces a deficit in ADP which is required for platelet aggregation. 28 Provided there is no transfusion reaction, the commonest cause of bleeding disorder following massive transfusion is dilutional thrombocytopenia ( Figure 5 ).
PSEUDOTHROMBOCYTOPENlA
It should be remembered that whenever an unexpected low platelet count is encountered, the causes of spurious low platelet count need to be excluded. Pseudothrombocytopenia is nowadays a common phenomenon. It is usually a laboratory artefact caused by platelets clumping together (by becoming coated with an IgM/IgG EDT Adependent anti platelet antibody or a platelet cold agglutinin) or adhering to neutrophils or monocyctes (platelet satellitism). This is reported as a low platelet count because most counts are now done on automated particle counters which will misdiagnose a clump of platelets as a larger cellular component. 40 CONCLUSION This review article has dealt with the nonobstetric maternal causes of bleeding in late pregnancy due to vascular, tissue, platelet or procoagulant disorders. In most of these conditions, a simple approach consisting of a history of bleeding or bruising, physical examination and simple haematological testing (bleeding time, coagulation screen) will often identify most significant causes of bleeding.
Secondary thrombocytopenia such as occurs in eclamptic patients and parturients with haemolytic anaemias and disseminated intravascular coagulation which occurs following abruptio placentae, intrauterine fetal death and other conditions of pregnancy have been specifically excluded in this review.
